A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?

Annals of Clinical Biochemistry

Volumn 47, Issue 4, 2010, Pages 292-300

  Bushe, Chris J ^a   Bradley, Andrew ^a   Pendlebury, John ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Ramsgate House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PROLACTIN;

BONE DENSITY; BREAST CANCER; CLINICAL ASSESSMENT; CLINICAL LABORATORY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; HYPERPROLACTINEMIA; MENTAL DISEASE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOCHEMISTRY; GUIDELINES AS TOPIC; HUMANS; HYPERPROLACTINEMIA; MENTAL DISORDERS; PROLACTIN;

EID: 77954421690     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2010.010025     Document Type: Review

References (83)

1. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-314 (Pubitemid 39388605)
2. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008;22(Suppl.):46-55
3. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psych 2007;190:129-34
4. Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 2008;22(Suppl.):20-7
5. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009;29:64-73
6. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? J Psychopharmacol 2008;22(Suppl.):12-9
7. Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22(Suppl.):98-103
8. Barnett AH, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007;21:357-73
9. Riddle O, Bates RW, Dykshorn SW. The preparation, identification and assay of prolactin - a hormone of the anterior pituitary. Am J Physiol 1933;105:191-216
10. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523-631
11. Kohen D, Wildgust HJ. The evolution of hyperprolactinaemia as an entity in psychiatric patients. J Psychopharmacol 2008;22(Suppl.):6-11
12. Arita J, Kojoma Y, Kimura F. Identification by the sequential call immunoblot assay of a subpopulation of rat dopamine-unresponsive lactotrophs. Endocrinology 1991;128:1887-94
13. Horseman ND, Yu-Lee LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin and hematopoietic cytokines. Endocr Rev 1994;15:627-49
14. Cooke NE, Corr D, Shine J, Baxter JD, Martial JA. Human prolactin cDNA structural analysis and evolutionary comparisons. J Biol Chem 1981;256:4007-16
15. Holt RIG. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol 2008;22(Suppl.):28-37
16. Garde AH, Hansen AM, Skovgaard LT, Christensen JM. Seasonal and biological variation of blood concentrations of total cholesterol, dehydroepiandrosterone sulfate, hemoglobin A (1c), IgA, prolactin, and free testosterone in healthy women. Clin Chem 2000;46:551-9 (Erratum in Clin Chem 2001;47:1877)
17. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22:724-63
18. Jeffcoate SL, Bacon RRA, Beastall GH, Diver MJ, Franks S, Seth J. Assays for prolactin:guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem 1986;23:638-51
19. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007;21:768-73 (Pubitemid 47437921)
20. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RH, O'Keane V. Effects of long term prolactin raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psych 2004;184:503-8 (Pubitemid 38725710)
21. Johnsen E, Kroken RA, Abaza M, Olberg H, Jørgensen HA. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol 2008;28:686-90
22. McEvoy JP, Lieberman JA, Perkins PO, et al. Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of early psychosis: a randomised, double blind 52 week comparison. Am J Psych 2007;164:1050-60
23. Vanderpump MP, French JM, Appleton D, Tunbridge WM, Kendall-Taylor P. The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort. Clin Endocrinol 1998;48:39-44 (Pubitemid 28122431)
24. Greer ME, Moraczewski T, Rakoff JS. Prevalence of hyperprolactinemia in anovulatory women. Obstet Gynecol 1980;56:65-9
25. De Rosa M, Zarrilli S, Di Sarno A, et al. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine 2003;20:75-82 (Pubitemid 36515190)
26. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000;85:3053-7
27. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65:265-73
28. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. Can Med Assoc J 2003;169:575-81
29. van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. J Bipolar Disord 2008;10:342-8 (Pubitemid 351637699)
30. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
31. Clemens JA, Smalstig EB, Sawyer BD. Antipsychotic drugs stimulate prolactin release. Psychopharmacology 1974;40:123-7
32. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73 (Pubitemid 26112775)
33. Seeman P. Atypical antipsychotics: mechanisms of action. Can J Psych 2002;47:27-38
34. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psych 2002;159:133-5
35. Kapur S, Langlois X, Vinken P, Megens AAHP, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood - brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302:1129-34 (Pubitemid 34920235)
36. Brown GM, Verhaegan H, Van Wimersma Greidanus TB, Brugmans J. Endocrine effects of domperidone: a peripheral dopamine blocking agent. Clin Endocrinol (Oxf) 1981;15:275-82 (Pubitemid 11063674)
37. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psych 2005;162:1010-2 (Pubitemid 40676220)
38. Reuwer AQ, Twickler MT, Hutten BA, et al. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet 2009;2(4):389-95
39. Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia; relationship to medication and endocrine variables. Schizophr Res 2007;93:136-43 (Pubitemid 46817924)
40. O'keane V. Antipsychotic induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008;22(Suppl.):70-5
41. Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S. Sexual function and gonadal hormones in patients taking antispychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psych 2007;68:361-7 (Pubitemid 46506799)
42. O'Keane V, Meaney AM. Antipsychotic drugs. A new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005;25:26-31
43. Huber TJ, Tettenborn C, Leifke E, Emrich HM. Sex hormones in psychotic men. Psychoneuroendocrinology 2005;30:111-4
44. Bergemann N, Mundt C, Parzer P, et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005;73:357-66
45. Knegtering H, van den Bosch R, Castelein S, Bruggeman R, Sytema S, van Os J. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology 2008;33:711-7
46. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psych 2007;164:1404-10
47. Kinon B, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinaemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006;31:577-88
48. Abel KM, Heatlie HF, Howard LM, Webb RT. Sex- and age-specific incidence of fractures in mental illness: a historical, population-based cohort study. J Clin Psych 2008;69:1398-403
49. Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence. A systematic review of clinical studies. Schizophr Res 2009;114:6-16
50. Ferlay J, Bray F, Pisani P, et al. Globocan 2002. Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0: IARC CancerBase no.5. Lyon: IARCPress, 2004
51. Office for National Statistics. Cancer Statistics registrations: Registrations of cancer diagnosed in 2004, England. Series MB1 no.35. 2007, National Statistics: London
52. Catts VS, Catts SV, O'Toole BI, Frost ADJ. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psych Scand 2008;117:323-36
53. Hippisley-Cox J, Vinogradova Y, Coupland C, Parker C. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psych 2007;64:1368-76
54. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F. Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Cell Mol Life Sci 2009;66(3):447-59
55. Tworoger S, Eliassen H, Sluss P, Hankinson S. A prospective study of plasma prolactin concentrations and the risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007;25:1-7
56. Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. Cancer Lett 2006;243:160-9
57. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominantly premenopausal women. Cancer Res 2006;66:2476-82
58. Wang PS, Walker AM, Tsuang MT. Dopamine antagonists and the development of breast cancer. Arch Gen Psych 2002;59:1147-54
59. Stocks T, Rapp K, Bjørge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 2009;6(12):e1000201. Epub 22 Dec 2009
60. Szarfman A, Tonning J, Levine J, Doraiswamy PM. Atypical antipsychotics and pituitary tumours: a pharmacovigilance study. Pharmacotherapy 2006;26:748-58
61. Akkaya C, Kaya B, Kotan Z, Sarandol A, Ersoy C, Kirli S. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. J Psychopharmacol 2008;23:723-6
62. Poyraz BC, Aksoy C, Balcioǧlu I. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. Eur Neuropsychopharmacol 2008;18:667-72
63. Smith S, Wheeler MJ, Murray R. The effects of antipsychotic induced hyperprolactinaemia on the hypothalamic - pituitary - gonadal axis. J Clin Psychopharmacol 2002;22:109-14
64. Becker D, Liver O, Mester M, Rapoport M, Weizman A, Weiss M. Risperidone but not olanzapine decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psych 2003;64:761-6
65. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004;64:6814-19 (Pubitemid 39297946)
66. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL.Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2008;116:43-50
67. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
68. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61 (Pubitemid 46178537)
69. Kleinberg DL, Davis JM, De Coster R. Prolactin levels and adverse effects in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61 (Pubitemid 29047332)
70. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
71. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first episode psychosis: a long term randomised trial. Am J Psych 2005;162:947-53
72. Jung DU, Sea YS, Park JH, et al. The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol 2005;25:613-5
73. Crawford AM, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54
74. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-7 (Pubitemid 39574406)
75. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psych 2007;22:433-43
76. Kane J, Meltzer H, Carson W, McQuade R, Marcus R, Sanchez R. Aripiprazole for treatment resistant schizophrenia: results of a multicenter randomised double-blind comparison study versus perphenazine. J Clin Psych 2007;68:213-23
77. Bushe C, Sniadecki J, Bradley AJ, Hoffman VP. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol, 2008 (in press). Epub 17 Nov 2008
78. National Institute for Health and Clinical Excellence (NICE). Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE clinical guideline 38, 2006 (cited 14 March 2009) See www.nice.org.uk/CG038
79. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines. 9th edn. London: Informa Healthcare, 2007
80. Falkai P, Wobrock T, Lieberman J, et al. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psych 2006;7:5-40
81. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association; Steering Committee on Practice Guidelines 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psych 2004;161(Suppl.):1-56
82. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psych 2004;161:1334-49
83. Pollock A, McLaren EH. Serum prolactin concentrations in patients taking neuroleptic drugs. Clin Endocrinol 1998;49:513-6 (Pubitemid 28475345)